Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting

No Thumbnail Available

Click here to download

0997.htm (5.06 KB)

Date

2018

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

functioning gastroenteropancreatic neuroendocrine tumors, 68Ga-DOTATATE, 177Lu-DOTATATE, neuroendocrine tumor, peptide receptor radionuclide therapy

Source

Nuclear Medicine Communications, 2018. Vol. 39 (12): pp. 1143-1149

URI

http://hdl.handle.net/123456789/18622

Collections

2018